Connect with us

Fetzima (levomilnacipran)

Levomilnacipran (or FETZIMA®) is mainly prescribed to treat major depressive disorder.

Status: ACTIVE

Class: Serotonin-norepinephrine Reuptake Inhibitor (SNRI)

FDA Approval: 2013

Dosage Forms: 20 mg, 40 mg, 80 mg, 120 mg

Biological Half-life: 12 hours

Side Effects: Dizziness, nausea, sweating, constipation, insomnia, high blood pressure, tachycardia, urinary hesitancy, erectile dysfunction

Routes of Administration: Oral

Pregnancy Category: C (US)


Twitter Feed

Gene discovery may explain why Lithium doesn't work for all patients

Researchers found insomnia may increase risk of mood disorder in teens #mentalhealth @PittTweet

Can Tylenol provide relief for social media anxiety? #FOMO #socialanxiety #cyberpsychology